We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
Information and guidance on group A streptococcal infections.
Background information and advice on coronavirus (COVID-19) for health and care professionals.
This guidance provides information on COVID-19 in homelessness, domestic abuse refuge, respite room and asylum seeker accommodation settings.
Information for health professionals on the epidemiology, transmission and prevention of Chlamydia abortus which can cause stillbirth or abortion in humans.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Information for healthcare professionals on how pulse oximeters are regulated, home use and issues to look out for when using the devices
Advice and guidance on the health needs of migrant patients from India for healthcare practitioners.
Guidance primarily aimed at local responders covering some humanitarian issues that may arise during the recovery phase of an emergency in the UK.
Information for clinicians on the characteristics, diagnosis and epidemiology of infections caused by Chlamydia psittaci.
The characteristics, diagnosis, management, surveillance and epidemiology of Pseudomonas aeruginosa.
Clinicians are provided with actions to complete when managing infectious diseases in the asylum seeker population.
Past and current clinical trials into therapeutic and antiviral treatments for COVID-19, how to take part, and which treatments have proven to be effective.
This document explains: how patients are tested and treated, and steps in place to prevent its spread.
Advice and guidance on the health needs of migrant patients from Iran for healthcare practitioners.
Guidance for schools in England on using emergency inhalers.
Find out about the long-term effects some people can have after having COVID-19.
Information for clinicians on diagnosis and notification of Shiga toxin-producing Escherichia coli (STEC) and haemolytic uraemic syndrome (HUS).
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.